Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Shankar Biswas
Institutions:
Ivano-Frankivsk National Medical University,
Sharda University
Observed institutions:
Ivano-Frankivsk National Medical University,
Sharda University
ORCID:
0009-0005-2421-3953
Observed ORCID:
0009-0005-2421-3953
OpenAlex ID:
A5137275965
Age confounding in HIV-associated progressive multifocal leukoencephalopathy prognosis
2026
·
Sindhu Vasireddy
, Shankar Biswas
, et al.
·
Brain
·
1
Real-world comparative safety and survival of alpelisib-fulvestrant versus capivasertib-fulvestrant in HR+/HER2− metastatic breast cancer: A propensity score–matched analysis.
2026
·
Shankar Biswas
, Yashasvi Srivastava
, et al.
·
Journal of Clinical Oncology
·
1
Artificial intelligence–guided microsatellite instability classification in colorectal cancer (CRC): EfficientNet-based histopathology analysis for precision treatment planning.
2026
·
Hammad Khan
, Elangovan Krishnan
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Differential risk of interstitial lung disease with DXd-based versus non-DXd TROP2 antibody-drug conjugates: A systematic review and meta-analysis.
2026
·
Prahlad Rao Kulkarni
, Shankar Biswas
, et al.
·
Journal of Clinical Oncology
·
1
PB3455 Direct Oral Anticoagulants Versus Direct Thrombin Inhibitors for Heparin-Induced Thrombocytopenia: A Propensity Score-Matched Analysis Using MIMIC-IV
2026
·
Shankar Biswas
, Yashasvi Srivastava
, et al.
·
Research and Practice in Thrombosis and Haemostasis
PDF
MCL-524: Comparative Cardiac Safety of Covalent and Noncovalent Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: A Multi-Center Retrospective Cohort Study
2026
·
Aditya Anand
, Shankar Biswas
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: MCL-1257: Pirtobrutinib-First vs Brexucabtagene Autoleucel–First Sequencing Post Covalent BTK Inhibitor Failure in Mantle Cell Lymphoma: A Propensity-Matched Real-World Analysis
2026
·
Shankar Biswas
, Suhail Sapkota
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
MDS-1311: Survival and Toxicity Outcomes With Hypomethylating Agent Plus Venetoclax vs Hypomethylating Agent Alone in Higher-Risk Myelodysplastic Syndrome: A Propensity-Matched Retrospective Cohort Study
2026
·
Shankar Biswas
, Kumar Anmol
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: MDS-1311: Survival and Toxicity Outcomes With Hypomethylating Agent Plus Venetoclax vs Hypomethylating Agent Alone in Higher-Risk Myelodysplastic Syndrome: A Propensity-Matched Retrospective Cohort Study
2026
·
Shankar Biswas
, Kumar Anmol
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
MPN-1283: Direct Oral Anticoagulants Versus Warfarin in Philadelphia-Negative Myeloproliferative Neoplasms With Atrial Fibrillation: A Propensity-Matched Retrospective Cohort Study
2026
·
Kumar Anmol
, Shankar Biswas
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: MPN-1283: Direct Oral Anticoagulants Versus Warfarin in Philadelphia-Negative Myeloproliferative Neoplasms With Atrial Fibrillation: A Propensity-Matched Retrospective Cohort Study
2026
·
Kumar Anmol
, Shankar Biswas
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
CT-1462: Efficacy and Safety of Bruton's Tyrosine Kinase Inhibitors in Primary Immune Thrombocytopenia: A Systematic Review and Meta-Analysis
2026
·
Gunn Goel
, Sarthak Wadhera
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
MCL-1233: Clinical Outcomes Following Ibrutinib Withdrawal in Mantle Cell Lymphoma: A TriNetX Analysis
2026
·
Suhail Sapkota
, Shankar Biswas
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
MDS-1271: Comparative Outcomes With Luspatercept Versus Erythropoiesis-Stimulating Agents in Lower-Risk Myelodysplastic Syndromes: A Propensity Score-Matched Retrospective Cohort Study
2026
·
Shankar Biswas
, Kumar Anmol
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
AML-867: Postmarketing Safety Signals of Revumenib (Menin-KMT2A Inhibitor) vs Acute Myeloid Leukemia-Targeted Therapies: A Class-Restricted Disproportionality Analysis of the FDA Adverse Event Monitoring System (2016–2026)
2026
·
Arashdeep Singh
, Sidharth Mahajan
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
MPN-571: Machine Learning-Based Model for Renal Replacement Therapy Risk Stratification in Tumor Lysis Syndrome: Development and External Validation Across MIMIC-IV and eICU Cohorts
2026
·
Prahlad Rao Kulkarni
, Srujan Mallagundla
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
AML-1211: Competing Risks Analysis of Age-Related and Temporal Trends in Acute Myeloid Leukemia Mortality: A SEER-Based Study (2000–2023)
2026
·
Ashesh Kumar
, Shiwani Keswani
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: AML-867: Postmarketing Safety Signals of Revumenib (Menin-KMT2A Inhibitor) vs Acute Myeloid Leukemia-Targeted Therapies: A Class-Restricted Disproportionality Analysis of the FDA Adverse Event Monitoring System (2016–2026)
2026
·
Arashdeep Singh
, Sidharth Mahajan
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
MDS-1298: Two-Year Outcomes of Iron Chelation Therapy in Transfusion-Exposed Patients With Myelodysplastic Syndromes: A Propensity Score-Matched TriNetX Analysis
2026
·
Kofi Boakye Opoku
, Shankar Biswas
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: CT-1462: Efficacy and Safety of Bruton's Tyrosine Kinase Inhibitors in Primary Immune Thrombocytopenia: A Systematic Review and Meta-Analysis
2026
·
Gunn Goel
, Sarthak Wadhera
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: AML-1211: Competing Risks Analysis of Age-Related and Temporal Trends in Acute Myeloid Leukemia Mortality: A SEER-Based Study (2000–2023)
2026
·
Ashesh Kumar
, Shiwani Keswani
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: MDS-1271: Comparative Outcomes With Luspatercept Versus Erythropoiesis-Stimulating Agents in Lower-Risk Myelodysplastic Syndromes: A Propensity Score-Matched Retrospective Cohort Study
2026
·
Shankar Biswas
, Kumar Anmol
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-1234: Temporal Improvements in Survival and Independent Prognostic Factors in Multiple Myeloma: A Large Population-Based Cohort Study
2026
·
Sumeet Kumar
, Shiwani Keswani
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
MCL-1257: Pirtobrutinib-First vs Brexucabtagene Autoleucel–First Sequencing Post Covalent BTK Inhibitor Failure in Mantle Cell Lymphoma: A Propensity-Matched Real-World Analysis
2026
·
Shankar Biswas
, Suhail Sapkota
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: MDS-1298: Two-Year Outcomes of Iron Chelation Therapy in Transfusion-Exposed Patients With Myelodysplastic Syndromes: A Propensity Score–Matched TriNetX Analysis
2026
·
Kofi Boakye Opoku
, Shankar Biswas
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Show more works
View as search
Works count:
52
Citation count:
4
H-index:
1
I10-index:
Year
Topic
Type